awmsg logo



bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy®)


Reference No. 3414


Appraisal information

bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy®) 50 mg/200 mg/25 mg film-coated tablet


Company: Gilead Sciences Ltd
BNF category: Infections
NMG meeting date: 10/10/2018
AWMSG meeting date: 14/11/2018
   
   
Submission Type: Full Submission
Status: In progress
Advice No: Not available
Ratification by Welsh Government: Not available

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

Indication

Treatment of adults infected with human immunodeficiency virus 1 without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir
Preliminary Appraisal Recommendation (PAR)
Download
Company Response to the Preliminary Appraisal Recommendation (CR PAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download